A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP)

Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2015

At a glance

  • Drugs Nemonoxacin (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 20 Sep 2013 New source identified and integrated (ClinicalTrials.gov: NCT01944774)
    • 16 May 2013 Status changed from planning to recruiting, based on information in a TaiGen Biotechnology media release.
    • 12 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top